stockportfolio.pro
Stocks / BCAX vs HROW
BCAX vs HROW
Bicara Therapeutics Inc. and Harrow, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bicara Therapeutics Inc. (BCAX) | Harrow, Inc. (HROW) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $0 | $272.30M |
| Net income (latest FY) | $-137.95M | $-5.14M |
| Revenue growth (5y CAGR) | — | 41.0% |
| Net margin | — | -1.9% |
| Return on equity | -34.4% | -9.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BCAX — free Open HROW — freeFrequently asked questions
Which is bigger, BCAX or HROW?
Harrow, Inc. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, BCAX or HROW?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.